EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency

Mendy Ter Avest iD, Simon E Koele iD, Nicole C A J van de Kar, Saskia M C Langemeijer, Rob Ter Heine iD

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70651 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Mendy Ter Avest und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Pharmacology & Toxicology, Radboudumc, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Antibodies, Monoclonal, Humanized, Models, Biological. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors. Since exposure often exceeds pharmacokinetic targets and varies with body weight, we aimed to explored individualized dosing of crovalimab using clinical trial simulations to optimize therapy.

Methods

We compared standard, weight‐based and therapeutic drug monitoring (TDM)‐guided regimens in treatment‐naïve PNH patients over 52 weeks by means of clinical trial simulations based on the population pharmacokinetic model developed by the market authorization holder.

Results

Maintenance‐phase crovalimab concentrations were generally supratherapeutic with substantial variability. Weight‐based dosing reduced this variability, while TDM‐guided dosing further minimized it and allowed dose intervals to be prolonged in 24% of patients to a mean of 5.0 weeks, while maintaining exposure comparable to the standard regimen.

Conclusion

Individualized dosing of crovalimab may reduce exposure variability and enable less frequent dosing, supporting the feasibility of more flexible cost‐effective and patient‐tailored treatment regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemoglobinuria, ParoxysmalAntibodies, Monoclonal, HumanizedModels, BiologicalHumansComputer SimulationFemaleCost-Benefit AnalysisAdultDrug MonitoringMaleMiddle AgedBody WeightPrecision MedicineDose-Response Relationship, DrugAged

Stichwörter der Autor:innen

crovalimabparoxysmal nocturnal haemoglobinuriapharmacodynamicspharmacokinetics

Substanzen

Antibodies, Monoclonal, HumanizedCrovalimab

Autor:innen und Institutionen

  • Department of Pharmacy, Pharmacology & Toxicology, Radboudumc, Nijmegen, The Netherlands.
  • Department of Paediatric Nephrology, Radboudumc, Nijmegen, The Netherlands.
  • Department of Haematology, Radboudumc, Nijmegen, The Netherlands.

ORCID-Profile: Mendy Ter Avest, Simon E Koele, Rob Ter Heine

Zitieren

APA

Ter Avest, M., Koele, S. E., van de Kar, N. C. A. J., Langemeijer, S. M. C., & Ter Heine, R. (2026). Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70651

Vancouver

Ter Avest M, Koele SE, van de Kar NCAJ, Langemeijer SMC, Ter Heine R. Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70651

BibTeX
@article{TerAvest2026,
  author = {Ter Avest, Mendy and Koele, Simon E and van de Kar, Nicole C A J and Langemeijer, Saskia M C and Ter Heine, Rob},
  title = {Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70651}
}
Kostenlos starten →